|
|
|
|
|
|
|
Regulus Therapeutics (RGLS)
|
|
0.6596 0.004 (0.58%)
|
04-18 16:00
|
|
Open:
|
0.6566
|
Pre. Close:
|
0.6558
|
|
High:
|
0.675
|
Low:
|
0.6372
|
|
Volume:
|
332,032
|
Market Cap:
|
69M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
0.682 - 0.685
|
0.685 - 0.688
|
|
Low:
|
0.631 - 0.635
|
0.635 - 0.639
|
|
Close:
|
0.654 - 0.661
|
0.661 - 0.666
|
|
|
|
Technical analysis (as of: 2018-04-18 4:43:55 PM)
|
|
Overall:
|
 
|
|
Stoxline rating system posted a NEUTRAL today, downgraded from higher rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.
|
|
Target:
|
Six months: 0.92 One year: 1.04
|
|
Support:
|
Support1: 0.63 Support2: 0.52
|
|
Resistance:
|
Resistance1:
0.79 Resistance2: 0.89
|
|
Pivot:
|
0.67
|
|
Moving Averages:
|
MA(5): 0.65  MA(20): 0.71
MA(100): 1.01 MA(250): 1.11
|
|
MACD:
|
MACD(12,26):
-0.08 Signal(12,26,9): -0.09
|
|
%K %D:
|
%K(14,3): 13.42 %D(3): 9.10
|
|
RSI:
|
RSI(14): 32.71
|
|
52-Week:
|
High: 1.95
Low: 0.63 Change(%): -56.0
|
|
Average Vol(K):
|
3-Month: 56833
10-Days 35005
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.RGLS has closed above bottom band by 40.7%. Bollinger Bands are 59.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to RGLS's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-04-17T16:10:00-04:00
Kathryn J. Collier Joins Regulus Board of Directors
2018-03-28T08:39:34-04:00
Premarket analyst action - healthcare
2018-03-20T16:15:00-04:00
Regulus to Present at the Needham Healthcare Conference
2018-03-08T12:38:01-05:00
Midday Gainers / Losers (3/8/2018)
2018-03-07T22:45:49-05:00
Regulus Therapeutics' (RGLS) CEO Jay Hagan on Q4 2017 Results - Earnings Call Transcript
2018-03-07T16:34:38-05:00
Regulus Therapeutics beats by $0.02, misses on revenue
2018-03-07T16:10:00-05:00
Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update
2018-03-05T19:01:00-05:00
Regulus to Present at the Cowen and Company 38th Annual Health Care Conference
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
